CClinicalTrials.gg
Status unknownNCT00316641Updated Nov 7, 2006

The Clinical Evaluation of Efficacy of Lipid-Lowing Tea on Hyperlipidemia Patients' Lipid Profiles

A Phase 3 interventional study of Lipid-lowing Tea in Hyperlipidemia, sponsored by China Medical University Hospital. Status unknown at 1 site in Taiwan. Open to participants aged 20 Years to 65 Years. Per ClinicalTrials.gov, last updated 2006-11-07.

Sponsored by China Medical University Hospital · Phase 3 and Interventional

The sponsor has not verified this record recently (last verified Mar 2006), so the status shown — last known as Recruiting — may be out of date.
Phase
Phase 3
Study type
Interventional
Allocation
Randomized
Ages
20 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to determine whether the Lipid-lowing Tea is effective and safe in the treatment of Hyperlipidemia Patients

02

Conditions studied

  • Hyperlipidemia
03

In context

Hyperlipidemias

821 studies on the registry are indexed under Hyperlipidemias; 105 are open to participants now.

Browse Hyperlipidemias studies →

Lead sponsor

China Medical University Hospital is the lead sponsor of 464 studies on the registry; 116 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 65 Years
Sexes eligible
All

Inclusion criteria

  • Patient aged 20-65 years;either sex
  • Patient diagnosed with hyperlipidemia(fasting levels of TC>=200mg/dL),or TG>=200mg/dL but \<400mg/dL,or LDL-C>=130mg/dL)
  • Patient who has signed the informed consent form

Exclusion criteria

Exclusion Criteria:

  • Patient with pregnancy (or child bearing potential),or in lactation
  • Patient with any lipid regulating agents within 4 weeks prior to study period
  • Patient currently taking concomitant medications, such as oral contraceptives, or any medical treatment capable of interfering with lipid metabolism(eg thiazides, β-blockers, cyclosporins, itraconazole erythromycin,and danazol)
  • Patient with medical history of hypothyroidism, pancreatitis, cholestasis, nephrotic syndrome, gall bladder disease, primary biliary cirrhosis.
  • Patient with liver dysfunction (SGOT or SGPT>2x ULN)
  • Patient with renal insufficiency (serum creatinine>1.3mg/dL)
  • Patient with myocardial infarction,cerebrovascular disease,or major operations within 6 months prior to the study period.
05

Study design

Phase
Phase 3
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double

Interventions

  • DrugLipid-lowing Tea
06

Study locations

1 of 1 sites recruiting
  • China Medical University Hospital
    Taichung, 404, Taiwan
    Recruiting
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 7, 2006, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00316641
Lead sponsor
China Medical University Hospital
First posted
Apr 21, 2006
Last update
Nov 7, 2006

Study contacts

Chia-I Tsai, V.S
Contact
josepho777@yahoo.com.tw
886-4-22052121 ext. 5065
Chia-I Tsai, V.S
principal investigator · China Medical University Hospital,Taichung,Taiwan
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2006. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion